- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 27.03. | SpyGlass Pharma: Stifel bekräftigt "Kaufen"-Rating und Kursziel von 42 Dollar | 1 | Investing.com Deutsch | ||
| 27.03. | Stifel reiterates Buy on SpyGlass Pharma stock, $42 target | 1 | Investing.com | ||
| 26.03. | SpyGlass Pharma, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 26.03. | SpyGlass Pharma, Inc. GAAP EPS of -$5.72 | 1 | Seeking Alpha | ||
| SPYGLASS PHARMA Aktie jetzt für 0€ handeln | |||||
| 26.03. | SpyGlass Pharma, Inc.: SpyGlass Pharma Reports Fourth Quarter and Full Year 2025 Earnings and Provides a Corporate Update | 116 | GlobeNewswire (Europe) | Successfully completed Initial Public Offering (IPO) in February 2026, raising $172.5 million and listing on Nasdaq.Reported positive topline 12-month data from Phase 1/2 trial of the Bimatoprost... ► Artikel lesen | |
| 26.03. | SpyGlass Pharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 10.03. | H.C. Wainwright initiates SpyGlass Pharma stock coverage with buy rating | 5 | Investing.com | ||
| 09.03. | SpyGlass Pharma, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 09.03. | SpyGlass Pharma, Inc.: SpyGlass Pharma Announces Positive Topline 12-Month Phase 1/2 Trial Results for Its Innovative BIM-IOL System | 429 | GlobeNewswire (Europe) | 97% of patients who received the BIM-IOL System off all topical IOP-lowering therapy at 12-months100% of BIM-IOL System patients achieved 20/32 or better BCDVA and a mean BCDVA equivalent to 20/20... ► Artikel lesen | |
| 03.03. | Leerink initiates SpyGlass Pharma stock with Outperform rating | 1 | Investing.com | ||
| 03.03. | Stifel initiates SpyGlass Pharma stock with buy rating on glaucoma device potential | 1 | Investing.com | ||
| 09.02. | SpyGlass Pharma, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 09.02. | SpyGlass Pharma, Inc.: SpyGlass Pharma Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Shares | 225 | GlobeNewswire (Europe) | ALISO VIEJO, Calif., Feb. 09, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) ("SpyGlass Pharma"), a late-stage biopharmaceutical company, today announced the closing of its initial public... ► Artikel lesen | |
| 06.02. | SpyGlass Pharma, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 06.02. | SpyGlass Pharma surges on public debut; AgomAb falls | 4 | Seeking Alpha | ||
| 06.02. | Chronic eye condition biotech SpyGlass Pharma prices IPO at $16 midpoint, raising $150 million | 2 | Renaissance Capital | ||
| 06.02. | Agomab, SpyGlass Pharma head to Nasdaq with IPOs totalling $350M | 1 | FierceBiotech | ||
| 06.02. | SpyGlass Pharma raises $150 million in IPO priced at $16 per share | 1 | Investing.com | ||
| 06.02. | SpyGlass Pharma Prices IPO At $16 Per Share | 731 | AFX News | WASHINGTON (dpa-AFX) - SpyGlass Pharma, Inc. (SGP), a late-stage biopharmaceutical company, announced the pricing of its initial public offering of 9.38 million shares at $16 per share.The company... ► Artikel lesen | |
| 06.02. | Agomab, SpyGlass Pharma bank a combined $350M in biotech IPOs | 1 | BioPharma Dive |
1 2 Weiter >>
29 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 35,045 | +0,04 % | QIAGEN N.V.: Qiagen Announces Form 20-F Annual Report Filing for 2025 Results | QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended... ► Artikel lesen | |
| IMMUNOVANT | 24,500 | -4,48 % | IMVT Stock Falls 2.4% as Batoclimab Misses Late-Stage Study Endpoints | ||
| DYNE THERAPEUTICS | 18,680 | -3,51 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces New Positive Cardiopulmonary Results from DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD) | - New analyses out to 24-months showed improvement in heart and lung function compared to expected declines in DMD natural history - - Data expand on previously reported results demonstrating that... ► Artikel lesen | |
| ENLIVEN THERAPEUTICS | 45,320 | -0,66 % | H.C. Wainwright reiterates Enliven Therapeutics stock rating on Terns deal details | ||
| ZENTALIS PHARMACEUTICALS | 6,630 | +50,17 % | Jefferies raises Zentalis stock price target on ovarian cancer trial data | ||
| VERA THERAPEUTICS | 45,000 | +9,92 % | Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| ALUMIS | 23,050 | +0,48 % | Alumis Inc.: Alumis' Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque Psoriasis | Envudeucitinib achieved robust PASI responses by Week 16, with significant continued improvements by Week 24 in PASI 90 (68.0%, 62.1%) and PASI 100 (41.0%, 39.5%)Quality-of-life improvements and itch... ► Artikel lesen | |
| MONTE ROSA THERAPEUTICS | 17,480 | -3,16 % | Monte Rosa Therapeutics, Inc.: Monte Rosa Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates | Positive interim Phase 1 data of NEK7-directed MGD MRT-8102 demonstrated profound CRP reductions in elevated CVD-risk subjects; readout of expanded part 3 CRP PoC trial (now called GFORCE-1) anticipated... ► Artikel lesen | |
| AMYLYX PHARMACEUTICALS | 16,360 | -5,54 % | Gubra A/S: Amylyx Pharmaceuticals Announces Nomination of AMX0318 as a Novel, Long-Acting GLP-1 Receptor Antagonist Development Candidate, Identified in Collaboration with Gubra | AMX0318 selected as development candidate after meeting key criteria, demonstrating a robust chemical stability profile, strong in vitro potency, evidence of in vivo efficacy and tolerability, high... ► Artikel lesen | |
| PHATHOM PHARMACEUTICALS | 12,630 | 0,00 % | Phathom Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results | FLORHAM PARK, N.J., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal... ► Artikel lesen | |
| ARCELLX | 114,83 | +0,03 % | Laufende Fusionskontrollverfahren: Gilead Sciences, Foster City, CA/USA; Erwerb sämtlicher Anteile an und Kontrolle über die Arcellx, Redwood City, CA/USA | Datum der Anmeldung:13.03.2026Aktenzeichen:B3-41/26Unternehmen:Gilead Sciences, Foster City, CA/USA; Erwerb sämtlicher Anteile an und Kontrolle über die Arcellx, Redwood City, CA/USAProduktmärkte:Hämatologie... ► Artikel lesen | |
| EVOTEC | 4,530 | +0,09 % | Aktien KW 15 Trump hält die Börsen im Griff. Wacklige Waffenruhe bringt Erholung, aber… News. Mutares. Evotec. TKMS. technotrans. HENSOLDT. Renk. Circus. Albis Leasing. Rheinmetall | Aktien - Erholungsaufatmer nach Waffenstillstand. Mit apokalyptischen Drohungen malte Trump die "Steinzeit" für den Iran an die Wand. Unter Vermittlung Pakistans - auch Chinas? - gab es kurz vorher... ► Artikel lesen | |
| BIONTECH | 81,40 | -0,06 % | BioNTech vs. Bioxyne: Wenn Forschungs-Riesen pausieren und Small Caps die Prognosen anheben | ||
| SUMMIT THERAPEUTICS | 19,670 | +1,86 % | Summit Therapeutics Has Scarcity Value In A Crowded Drug Race: Analyst | ||
| BEAM THERAPEUTICS | 27,450 | +4,21 % | Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development | Treatment with 60 mg of BEAM-302 Led to Mean Steady-state Total AAT Level of 16.1 µM and All Patients Consistently and Durably Above the 11 µM Protective AAT Threshold with up to 12 Months of Follow-up... ► Artikel lesen |
SPYGLASS PHARMA INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 20,820 Euro und damit -1,84 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SPYGLASS PHARMA INC finden Sie auf Wallstreet Online.